Ardigen

PhenAID platform - Transform HCS data into actionable insights with the power of AI

 

Discover PhenAID in Action: Request Your Demo Today

PhenAID Platform Capabilities

PhenAID Bridges the Gap Between
Cell Imaging and Small Molecule Design

PhenAID is more than just a platform. It's a comprehensive solution that seamlessly integrates the most recent advancements in AI, specifically computer vision and AI-chem, with molecular biology and medicinal chemistry. This unique approach enables us to bridge the gap between cell imaging and the design of desired small molecules.

Our platform uses AI for high-content screening analysis, making it possible to extract more information from your experiments. This is achieved by employing machine learning in phenotypic assays to bring a new level of precision and insight.

We are transforming the landscape of drug discovery with the power of AI, creating a tool that not only accelerates the process but also significantly enhances its potential outcomes.

1

PhenAID platform
empowers you to:

  •  
    - exhaustively search through chemical space
     
    - accelerate in silico optimization (even to 2 AI-Lab Cycles)
     
    - enhance Hit Rates with Tailored Libraries
     
    - precisely Pinpoint Desired Phenotypic Outcomes
     

Accelerate Drug Discovery Process

 As the standard drug design process is expensive and time-consuming, it can be improved with our AI-based solutions.

2

Increasing Your Success Rate
with Solutions Tailored to Your Needs

What Level of Customization Do You Need?

Whether you are just starting or have been in the field for some time, we fit into your needs by providing two approaches to collaboration. Our out-of-the-box Licensed Virtual Screening Platform gives you access to a cloud-based app as a ready-to-use solution. Whereas, Our Customized Virtual Screening Service enables integration with your internal data, pipelines, and system to maximize the utility of its usage.

 

Licensed Virtual Screening Platform:

12-01-1

Customized Virtual Screening Service:

Zrzut ekranu 2023-03-22 104639

Explore our knowledge base

Access detailed insights and real-world
applications of PhenAID platform

Empower your phenotypic
screening with AI

In the demanding field of drug discovery, your time and resources are invaluable. It's essential to maximize efficiency without compromising the depth of your analysis. Enter the age of AI-driven high-content screening, designed to streamline your processes and empower your decision-making.

Are you grappling with the complexities of cellular imaging and phenotypic data interpretation? We understand the challenges of transforming intricate data into actionable insights. Our AI-enhanced tools assist you in navigating through this complex landscape, allowing you to make better-informed decisions faster.

We recognize that detecting off-target drug effects and predicting phenotypic outcomes can be daunting tasks. Our solution is designed to tackle these challenges head-on, improving the hit rate in your drug screening and enabling the early identification of potential off-target effects.

High-throughput image analysis no longer needs to be an overwhelming task. With our user-friendly and efficient tools, you can turn this process into a valuable asset for your research, enabling you to delve deeper and further into your data.

We believe that the future of phenotypic screening lies in harnessing the power of AI. Whether you're working on cell painting assays or aiming to optimize your drug discovery process, we're here to support you every step of the way. Unleash the full potential of your research with our advanced AI capabilities.

It's not just about having data - it's about understanding it. Turn your data into insight with PhenAid.

Ardigen is a supporting partner
of the JUMP-CP Consortium

JUMP-CP consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set, corresponding to both genetic and chemical perturbations. It's members include 10 leading pharmaceutical companies (Amgen, AstraZeneca, Bayer, Biogen, Eisai, Janssen Pharmaceutica NV, Merck KGaA, Pfizer, Servier, and Takeda) and two non-profit research organizations, including the Broad Institute of MIT and Harvard and Ksilink. We are providing deep learning expertise to the consortium, leveraging a web application to facilitate the exploration of the JUMP-CP Cell Painting dataset.